Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | SVP, Planning and Business Dev | January 19, 2018 | January 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date January 19, 2018 · Filed January 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2028-01-19 | Direct | 500,000 |
Reported balance
After 2018-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-01-19 · Grant · Acquired 500,000 · Balance 500,000 F1: The option vests and becomes exercisable on the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial or comparable product occurs. |
| Common StockSEC Table I · non-derivative | Direct | 2 |
Reported balance
Holding disclosure · report date 2018-01-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2 |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial or comparable product occurs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 19, 2018 Filed Jan 19, 2018 22:40 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001140361-18-002638 · doc1.xml · derivative · entry 2 BERGSTEIN ADAM D. · CIK 0001728666 · SVP, Planning and Business Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-01-19 F1 · derivative.exercise_date: The option vests and becomes exercisable on the date on which the initial patient recruitment for the Company's Phase II lumbar clinical trial or comparable product occurs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.